Not a lot of science in calculating fair value Weazel, it's...

Not a lot of science in calculating fair value Weazel, it's either whateveryareckon, or it represents the negotiated price of an asset between willing buyers and sellers in an orderly market.

Presently, EYE Nova shares are trading solely upon the prospect of increased sales figures and a 'material improvement' to operating results or suchlike, without providing evidence. I won't speak on Stonks' behalf but I reckon he may have considered that the big sales pump, without qualifying the underlying cost structure and the possibility of declining cash reserves will change fair value instantly once those elements are known